Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.
Biodesix to Present Data from Three Studies Indicating the Utility of Blood-Based Diagnostic Tests at AACR Annual Meeting
Biodesix to present data from three studies indicating the utility of blood-based diagnostic tests at the AACR annual meeting
With positive coverage decisions from BCBS Florida and HCSC, 200 million Americans now have insurance coverage for VeriStrat testing.
Biodesix Presentation at Molecular Med Tri-Conference: “Blood-Based Cancer Immunotherapy Diagnostics”
Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.
Norgen Biotek Corp. Announces Supply Agreement with Biodesix Enabling the First EML4-ALK Liquid Biopsy Test with Results in 72-Hours
Biodesix has selected Norgen Biotek to supply sample preparation products for its EML4-ALK blood test.
Biodesix raised $22 million through the sale of series F preferred stock and other securities.
Biodesix CEO David Brunel will present a corporate overview on Deep Phenotyping, Machine Learning to Precision Medicine at the Leerink Partners Conference
GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment.
Biodesix to Present Data on Blood Based Diagnostic Tests for Patients with Non-Small Cell Lung Cancer (NSCLC)
Biodesix data on proteomic and genomic blood-based assays presented at EORTC
Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy; Biodesix’ blood test is independent of PD-L1 expression
Investigational blood test identifies patients with melanoma who are more likely to have improved survival on Nivolumab therapy.